AR123978A1 - Variantes de la interleucina-18 y métodos de uso - Google Patents
Variantes de la interleucina-18 y métodos de usoInfo
- Publication number
- AR123978A1 AR123978A1 ARP210103038A ARP210103038A AR123978A1 AR 123978 A1 AR123978 A1 AR 123978A1 AR P210103038 A ARP210103038 A AR P210103038A AR P210103038 A ARP210103038 A AR P210103038A AR 123978 A1 AR123978 A1 AR 123978A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide
- modified
- methods
- seq
- amino acid
- Prior art date
Links
- 102000003810 Interleukin-18 Human genes 0.000 title abstract 15
- 108090000171 Interleukin-18 Proteins 0.000 title abstract 15
- 238000000034 method Methods 0.000 title abstract 5
- 102000044166 interleukin-18 binding protein Human genes 0.000 abstract 6
- 108010070145 interleukin-18 binding protein Proteins 0.000 abstract 6
- 102000004557 Interleukin-18 Receptors Human genes 0.000 abstract 4
- 108010017537 Interleukin-18 Receptors Proteins 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 230000035772 mutation Effects 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 102220470467 Adenosine 5'-monophosphoramidase HINT2_C38S_mutation Human genes 0.000 abstract 1
- 102220517454 DDIT3 upstream open reading frame protein_C68Y_mutation Human genes 0.000 abstract 1
- 102220557454 Mitochondrial 2-oxoglutarate/malate carrier protein_C68V_mutation Human genes 0.000 abstract 1
- 102220472119 Protein Wnt-2_C68A_mutation Human genes 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102200149714 rs113604459 Human genes 0.000 abstract 1
- 102200105263 rs587777639 Human genes 0.000 abstract 1
- 230000007781 signaling event Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente divulgación provee composiciones y métodos que comprenden polipéptidos de IL-18 estabilizados para su uso en aplicaciones terapéuticas y no terapéuticas. En algunos casos, las proteínas de IL-18 estabilizadas proporcionan actividad de señalización de la IL-18 incluso en presencia de una molécula inhibidora como IL-18BP. En algunos casos, los polipéptidos de IL-18 muestran afinidad de unión preferencial por IL-18R en lugar de IL-18BP. También se proveen métodos de administración, métodos de tratamiento y métodos para producir polipéptidos activos. Reivindicación 1: Un polipéptido que es interleucina-18 (IL-18) modificada que preferentemente se une al receptor de la IL-18 (IL-18R) en lugar de a una proteína de unión a la IL-18 (IL-18BP) caracterizado porque comprende: (I) una secuencia de aminoácido que tiene un 85% o más de identidad de secuencia con la IL-18 de tipo natural (WT) como se describe en la SEQ ID n.º 30 o con la secuencia de aminoácido de la variante de IL-18 descrita en cualquiera de las SEQ ID nº 6, 87-91 y 16-21; y (II) mutaciones en las posiciones de aminoácido C38 y C68 en relación con la SEQ ID nº 30, donde dicha IL-18 modificada preferentemente se une al IL-18R en lugar de a la IL-18BP. Reivindicación 2: El polipéptido que es la IL-18 modificada de la reivindicación 1, caracterizado porque el polipéptido de IL-18 modificada no comprende residuos de cisteína que no son naturales al polipéptido de IL-18. Reivindicación 3: La composición de la reivindicación 1, caracterizada porque el polipéptido de IL-18 tiene una afinidad de unión por la IL-18BP que es menor que 0,6 nM. Reivindicación 4: El polipéptido que es la IL-18 modificada de la reivindicación 1, caracterizado porque la mutación en la posición C38 es C38S y la mutación en la posición C68 es C68S, C68G, C68A, C68V, C68D, C68E o C68N.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108794P | 2020-11-02 | 2020-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123978A1 true AR123978A1 (es) | 2023-02-01 |
Family
ID=81384408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103038A AR123978A1 (es) | 2020-11-02 | 2021-11-02 | Variantes de la interleucina-18 y métodos de uso |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11850276B2 (es) |
| EP (1) | EP4236990A1 (es) |
| JP (1) | JP2023550545A (es) |
| KR (1) | KR20230117120A (es) |
| CN (1) | CN116723851A (es) |
| AR (1) | AR123978A1 (es) |
| AU (1) | AU2021371040A1 (es) |
| CA (1) | CA3197145A1 (es) |
| GB (1) | GB2617483A (es) |
| IL (1) | IL302517A (es) |
| MX (1) | MX2023005068A (es) |
| TW (1) | TW202233657A (es) |
| WO (1) | WO2022094473A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023010021A1 (en) | 2021-07-27 | 2023-02-02 | Xencor, Inc. | Il-18-fc fusion proteins |
| WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
| WO2024044780A1 (en) * | 2022-08-26 | 2024-02-29 | Sutro Biopharma, Inc. | Interleukin-18 variants and uses thereof |
| WO2024051728A1 (en) * | 2022-09-06 | 2024-03-14 | I-Mab Biopharma Co., Ltd. | Il-18 variant polypeptides |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
| EP1669454A3 (en) | 1996-06-27 | 2009-04-01 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma |
| JP3955352B2 (ja) | 1997-02-25 | 2007-08-08 | 株式会社林原生物化学研究所 | 破骨細胞形成阻害剤 |
| TWI227136B (en) | 1998-05-21 | 2005-02-01 | Smithkline Beecham Corp | Novel pharmaceutical composition for the prevention and/or treatment of cancer |
| IL153201A0 (en) | 2000-06-02 | 2003-07-06 | Smithkline Beecham Corp | Methods of treating viral diseases with il-18 and il-18 combinations |
| ES2251610T3 (es) | 2001-03-08 | 2006-05-01 | Ares Trading S.A. | Mutantes de interleuquina-18, su produccion y su uso. |
| WO2004091517A2 (en) * | 2003-04-15 | 2004-10-28 | Smithkline Beecham Corporation | Conjugates comprising human il-18 and substitution mutants thereof |
| PT3536333T (pt) * | 2010-01-04 | 2022-11-11 | Mapi Pharma Ltd | Sistema de depósito compreendendo acetato de glatirâmero |
| WO2017102010A1 (en) | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
| IL272635B2 (en) * | 2017-09-06 | 2024-02-01 | Univ Yale | Variants of interleukin-18 and methods of use |
| US20210015891A1 (en) * | 2019-05-13 | 2021-01-21 | Simcha IL-18, Inc. | Interleukin-18 mimics and methods of use |
-
2021
- 2021-11-02 WO PCT/US2021/057741 patent/WO2022094473A1/en active Application Filing
- 2021-11-02 TW TW110140842A patent/TW202233657A/zh unknown
- 2021-11-02 CN CN202180089105.7A patent/CN116723851A/zh active Pending
- 2021-11-02 KR KR1020237018440A patent/KR20230117120A/ko unknown
- 2021-11-02 JP JP2023551948A patent/JP2023550545A/ja active Pending
- 2021-11-02 AR ARP210103038A patent/AR123978A1/es unknown
- 2021-11-02 EP EP21887776.9A patent/EP4236990A1/en active Pending
- 2021-11-02 AU AU2021371040A patent/AU2021371040A1/en active Pending
- 2021-11-02 MX MX2023005068A patent/MX2023005068A/es unknown
- 2021-11-02 GB GB2308183.9A patent/GB2617483A/en active Pending
- 2021-11-02 IL IL302517A patent/IL302517A/en unknown
- 2021-11-02 CA CA3197145A patent/CA3197145A1/en active Pending
-
2022
- 2022-12-01 US US18/060,816 patent/US11850276B2/en active Active
-
2023
- 2023-11-03 US US18/501,210 patent/US20240066100A1/en active Pending
- 2023-11-03 US US18/501,206 patent/US20240075104A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202233657A (zh) | 2022-09-01 |
| US20240075104A1 (en) | 2024-03-07 |
| AU2021371040A1 (en) | 2023-06-22 |
| US20230277625A1 (en) | 2023-09-07 |
| JP2023550545A (ja) | 2023-12-01 |
| US11850276B2 (en) | 2023-12-26 |
| CA3197145A1 (en) | 2022-05-05 |
| WO2022094473A1 (en) | 2022-05-05 |
| KR20230117120A (ko) | 2023-08-07 |
| GB202308183D0 (en) | 2023-07-19 |
| GB2617483A (en) | 2023-10-11 |
| CN116723851A (zh) | 2023-09-08 |
| EP4236990A1 (en) | 2023-09-06 |
| IL302517A (en) | 2023-07-01 |
| US20240066100A1 (en) | 2024-02-29 |
| MX2023005068A (es) | 2023-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123978A1 (es) | Variantes de la interleucina-18 y métodos de uso | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| DK1877435T4 (da) | Glucagon-lignende-peptid-2 (glp-2)-analoger | |
| PE20130593A1 (es) | DOMINIOS DE FIBRONECTINA TIPO III A LA DECIMA (10Fn3) MODIFICADOS DE UNION A SEROALBUMINA | |
| DK1844150T3 (da) | Rekombinant ekspression af proteiner i en to-kædet form med disulfidbroer | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| DE502005006284D1 (de) | Keratin-bindende polypeptide | |
| BRPI0811320A2 (pt) | Surfactantes reconstituídos com propriedades melhoradas | |
| PE20160507A1 (es) | Diferenciacion de celulas madre mesenquimales | |
| PE20090682A1 (es) | Secuencias peptidicas y composiciones | |
| BRPI0412799A (pt) | imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura | |
| PE20040677A1 (es) | Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria (pacap) | |
| US20210221866A1 (en) | Protease-resistant lipidated glp-1 analogs | |
| JP2019520333A (ja) | Ｍｉｃ−１化合物及びその使用 | |
| EA200900373A1 (ru) | Реконструированные сурфактанты, обладающие улучшенными свойствами | |
| ES2213861T3 (es) | Procedimiento de obtencion de ngf-beta activa. | |
| KR940019726A (ko) | 종양괴사인자- 알파 뮤테인 | |
| KR980002066A (ko) | 변이형 인간 성장호르몬 및 그의 용도 | |
| Baumann et al. | Identification of a potential modification site in human stromal cell‐derived factor‐1 | |
| PE20230486A1 (es) | Polipeptidos y sus usos | |
| KR102166543B1 (ko) | 켈로이드 억제용 조성물 및 그 억제 방법 | |
| Harris et al. | Chemical synthesis of γ‐secretase activating protein using pseudoglutamines as ligation sites | |
| AR123371A1 (es) | Proteínas il-2 glicosiladas y usos de estas | |
| KR102077984B1 (ko) | 피부 주름 예방 및 개선용 조성물 | |
| EA200601793A1 (ru) | Химерный гормон роста человека, полученный из изоформы плаценты и гипофиза, и способы получения указанной химеры |